RGEN logo

Repligen Corporation Stock Price

NasdaqGS:RGEN Community·US$8.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

RGEN Share Price Performance

US$155.08
16.18 (11.65%)
US$131.29
Fair Value
US$155.08
16.18 (11.65%)
18.1% overvalued intrinsic discount
US$131.29
Fair Value
Price US$155.08
AnalystLowTarget US$131.29
AnalystConsensusTarget US$187.00
AnalystHighTarget US$220.00

RGEN Community Narratives

AnalystLowTarget·
Fair Value US$131.29 18.1% overvalued intrinsic discount

Inflation And Deglobalization Risks Will Curtail Progress As China Recovers

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystConsensusTarget·
Fair Value US$187 17.1% undervalued intrinsic discount

Recovery In Industry Demand And Market Stability Will Drive Renewed Momentum

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AnalystHighTarget·
Fair Value US$220 29.5% undervalued intrinsic discount

Next-Generation Biologics And Automation Will Elevate Bioprocessing Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Updated Narratives

RGEN logo

Recovery In Industry Demand And Market Stability Will Drive Renewed Momentum

Fair Value: US$187 17.1% undervalued intrinsic discount
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RGEN logo

Inflation And Deglobalization Risks Will Curtail Progress As China Recovers

Fair Value: US$131.29 18.1% overvalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RGEN logo

Next-Generation Biologics And Automation Will Elevate Bioprocessing Demand

Fair Value: US$220 29.5% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

2 Risks
4 Rewards

Repligen Corporation Key Details

US$707.9m

Revenue

US$342.7m

Cost of Revenue

US$365.2m

Gross Profit

US$363.5m

Other Expenses

US$1.7m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
0.031
51.59%
0.25%
25.8%
View Full Analysis

About RGEN

Founded
1981
Employees
1778
CEO
Olivier Loeillot
WebsiteView website
www.repligen.com

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Recent RGEN News & Updates

Recent updates

No updates